Found 150 clinical trials
Sanofi Test Website carcinoma
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum et sapien non purus accumsan pulvinar eget ac tortor. Ut et sagittis libero, nec vestibulum quam. Aliquam non felis
- 0 views
- 01 Mar, 2024
- 1 location
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors
- 0 views
- 10 Jan, 2025
- 26 locations
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1
- 0 views
- 10 Jan, 2025
- 1 location
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
be a bypass signaling mechanism that allows these cancer cells to circumvent the selective pressure from TKIs. Recent data have suggested that these pathways compensate for each other in situations
- 0 views
- 10 Jan, 2025
- 4 locations
Personalized DC Vaccines in Non Small Cell Lung Cancer
in patients with advanced or recurrent metastatic NSCLC.
- 0 views
- 10 Jan, 2025
- 1 location
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- 0 views
- 10 Jan, 2025
- 1 location
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab
- 0 views
- 03 Jul, 2025
- 1 location
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
- 0 views
- 24 Jun, 2025